In vitro chemoresponse to cisplatin and outcomes in cervical cancer

Gynecologic Oncology

Volumn 130, Issue 1, 2013, Pages 188-191

  Grigsby, Perry W ^a,b,c   Zighelboim, Israel ^a,b   Powell, Matthew A ^a,b   Mutch, David G ^a,b   Schwarz, Julie K ^a,b  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Washington University in St Louis School of Medicine   (United States)

^c WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Chemoresponse; ChemoRT; Cisplatin

Indexed keywords

CISPLATIN; FLUORODEOXYGLUCOSE F 18;

ADENOCARCINOMA; ADULT; ARTICLE; CANCER PATIENT; CANCER STAGING; CANCER SURVIVAL; CHEMORADIOTHERAPY; CHEMOSENSITIVITY; CLINICAL ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN CELL; IN VITRO STUDY; LYMPH NODE METASTASIS; MULTIMODALITY CANCER THERAPY; OUTCOME ASSESSMENT; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RECURRENCE FREE SURVIVAL; RETROSPECTIVE STUDY; SCORING SYSTEM; SQUAMOUS CELL CARCINOMA; UTERINE CERVIX CANCER;

ADENOCARCINOMA; ANTINEOPLASTIC AGENTS; CARCINOMA, SQUAMOUS CELL; CHEMORADIOTHERAPY; CISPLATIN; DISEASE-FREE SURVIVAL; DRUG SCREENING ASSAYS, ANTITUMOR; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; MIDDLE AGED; POSITRON-EMISSION TOMOGRAPHY; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; UTERINE CERVICAL NEOPLASMS;

EID: 84879121031     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2013.04.005     Document Type: Article

References (20)

1. National Cancer Institute (NCI) NCI issues clinical announcement on cervical cancer: chemotherapy plus radiation improves survival: National Institutes of Health (press release) 1999 NCI Press Bethesda (MD)
2. W. Ziegler, and J.M. Kopp The effect of combined treatment of HeLa cells with cisplatin and irradiation upon survival and recovery from radiation damage Radiother Oncol 8 1987 71 78
3. P. Bonomi, and J. Blessing Randomized trial of three cisplatin dose schedules in squamous-cell carcinoma of the cervix. A Gynecologic Oncology Group study J Clin Oncol 3 1985 1079 1085
4. J.T. Thigpen, H. Shingleton, H. Homesley, L. Lagasse, and J.A. Blessing Cis-platinum in treatment of advanced or recurrent squamous cell carcinoma of the cervix: A phase II study of the Gynecologic Oncology Group Cancer 48 1981 899 903
5. Y. Xu, H. Yu, H. Qin, J. Kang, C. Yu, and J. Zhong Inhibition of autophagy enhances cisplatin cytotoxicity through endoplasmic reticulum stress in human cervical cancer cells Cancer Lett 314 2012 232 243
6. D. Schloffer, M. Horky, V. Kotala, and J. Wȩsierska-Ga̧dek Induction of cell cycle arrest and apoptosis in human cervix carcinoma cells during therapy by cisplatin Cancer Detect Prev 27 2003 481 493
7. J.A. Green, J.M. Kirwan, J.F. Tierney, P. Symonds, L. Fresco, and M. Collingwood Survival and recurrence after concomitant chemotherapy and radiotherapy for cancer of the uterine cervix: a systematic review and meta-analysis Lancet 358 2001 781 786
8. L.M. Randall, B.J. Monk, J. Moon, R. Parker, M. Al-Ghazi, and S. Wilczynski Prospective evaluation of an in vitro radiation resistance assay in locally advanced cancer of the uterine cervix: A Southwest Oncology Group study Gynecol Oncol 119 2010 417 421
9. P.W. Grigsby, C.M. Gan, T.D. Tillmanns, and G. del Priore In vitro chemoresponse analysis of cervical cancer patient specimens Oncologist 2013 (submitted for publication)
10. E.A. Kidd, B.A. Siegel, F. Dehdashti, J.S. Rader, S. Mutic, and D.G. Mutch Clinical outcomes of definitive intensity-modulated radiation therapy with fluorodeoxyglucose-positron emission tomography simulation in patients with locally advanced cervical cancer Int J Radiat Oncol Biol Phys 77 2010 1085 1091
11. S.L. Brower, J.E. Fensterer, and J.E. Bush The ChemoFx assay: an ex vivo chemosensitivity and resistance assay for predicting patient response to cancer chemotherapy Methods Mol Biol 414 2008 57 78
12. H.J. Long III, B.N. Bundy, E.C. Grendys Jr, J.A. Benda, D.S. McMeekin, and J. Sorosky Randomized phase III trial of cisplatin with or without topotecan in carcinoma of the uterine cervix: A Gynecologic Oncology Group study J Clin Oncol 23 2005 4626 4633
13. D.H. Moore, J.A. Blessing, R.P. McQuellon, H.T. Thaler, D. Cella, and J. Benda Phase III study of cisplatin with or without paclitaxel in stage IVB, recurrent, or persistent squamous cell carcinoma of the cervix: A Gynecologic Oncology Group study J Clin Oncol 22 2004 3113 3119
14. J.T. Thigpen, J.A. Blessing, P.J. DiSaia, W.C. Fowler Jr, and K.D. Hatch A randomized comparison of a rapid versus prolonged (24 hr) infusion of cisplatin in therapy of squamous cell carcinoma of the uterine cervix: A Gynecologic Oncology Group study Gynecol Oncol 32 1989 198 202
15. M.E. Potter, K.D. Hatch, M.Y. Potter, H.M. Shingleton, and V.V. Baker Factors affecting the response of recurrent squamous cell carcinoma of the cervix to cisplatin Cancer 63 1989 1283 1286
16. S.B. Lele, and M.S. Piver Weekly cisplatin induction chemotherapy in the treatment of recurrent cervical carcinoma Gynecol Oncol 33 1989 6 8
17. G.A. Omura, J.A. Blessing, L. Vaccarello, M.L. Berman, D.L. Clarke-Pearson, and D.G. Mutch Randomized trial of cisplatin versus cisplatin plus mitolactol versus cisplatin plus ifosfamide in advanced squamous carcinoma of the cervix: A Gynecologic Oncology Group study J Clin Oncol 15 1997 165 171
18. H.J. Burstein, P.B. Mangu, M.R. Somerfield, D. Schrag, D. Samson, and L. Holt American Society of Clinical Oncology clinical practice guideline update on the use of chemotherapy sensitivity and resistance assays J Clin Oncol 29 2011 3328 3330
19. J.K. Schwarz, J.E. Payton, R. Rashmi, T. Xiang, Y. Jia, and P. Huettner Pathway-specific analysis of gene expression data identifies the PI3K/Akt pathway as a novel therapeutic target in cervical cancer Clin Cancer Res 18 2012 1464 1471
20. J.B. McIntyre, J.S. Wu, P.S. Craighead, T. Phan, M. Kobel, and S.P. Lees-Miller PIK3CA mutational status and overall survival in patients with cervical cancer treated with radical chemoradiotherapy Gynecol Oncol 128 2013 409 414